Methotrexate (MTX) is commonly used in the prophylaxis of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In order to evaluate the efficacy and safety of low-dose MTX treatment in patients with GVHD after allo-HSCT, 38 patients with acute GVHD (aGVHD), chronic GVHD (cGVHD) or GVHD post-donor lymphocyte infusion (post-DLI GVHD) after allo-HSCT received intravenous MTX at a dose of 5 or 10 mg every 5-7 days until a complete or partial response was seen, or there was treatment failure or intolerable side effects. The overall response rate was 94.7% (18/19 patients) in patients with aGVHD, 76.2% (16/21 patients) in patients with cGVHD and 2/2 in patients with post-DLI GVHD. The response rate for GVHD involving various organs was 100% in skin, 75% in gut, 55.6% in liver, 75% in mouth and 100% in the eye, among all enrolled patients. Side effects were minor. Short-term, low-dose MTX is a tolerable and an effective regimen for patients with aGVHD, cGVHD or post-DLI GVHD after allo-HSCT.
geneic; methotrexate; graft-versus-host disease Graft-versus-host disease (GVHD) is the most common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The incidences of acute GVHD (aGVHD) and chronic GVHD (cGVHD) are 30-80% and 30-80%, respectively.
1-3 GVHD itself and treatment-related infections are the principal causes of nonrelapse mortality. [2] [3] [4] It is thus necessary to develop novel therapeutic strategies. For aGVHD after methotrexate (MTX) alone or MTX in combination with cyclosporine A (CsA) as prophylaxis regimens, methylprednisolone (MP) is the best initial therapy. 4 Prednisone and CsA are considered as the first-line therapy for patients with cGVHD. 5 Other therapeutic options for acute or chronic GVHD are anti-thymocyte globulin (ATG), mycophenolate mofetil (MMF), tacrolimus (FK506), azathioprine, thalidomide, monoclonal antibodies directly against CD3, CD25, CD52, cytotoxic T-lymphocyte antigen (CTLA)-4 or tumor necrosis factor (TNF)-alpha, extracorporeal photochemotherapy and PUVA therapy. 1, 2, 4, [6] [7] [8] [9] Most immunosuppressive agents require continuous administration of the drug to be effective. Consequently, infectious complications are frequently observed and tremendously increase treatment cost.
One of the cytotoxic and immunosuppressive agents, azathioprine has been successfully used in the treatment of cGVHD. Thus, we hypothesized that MTX may have a similar effect on GVHD. To date, MTX has always been used as a single agent in the prevention of aGVHD after allo-HSCT, or as part of a combined regimen for treating cGVHD in both adult and pediatric patients. [10] [11] [12] [13] [14] There are no published data on the efficacy and the safety of low-dose MTX treatment in patients with acute or chronic GVHD.
To extend our experience with this medication, we performed a clinical study using low-dose MTX to treat patients with aGVHD, cGVHD or GVHD post donor lymphocyte infusion (post-DLI GVHD). This preliminary report summarizes the results in 38 patients.
Materials and methods

Patients
The study was approved by the Institutional Review Board of the Peking University Institute of Hematology. All patients and donors gave written informed consent before participating in the study. Between July 2001 and May 2004, 38 patients were enrolled, including 15 with aGVHD, 17 with cGVHD, four who received MTX when they developed aGVHD and cGVHD, and two with post-DLI GVHD. Four patients with aGVHD and subsequently cGVHD were assigned and evaluated in both Group aGVHD and Group cGVHD. Their characteristics upon entry are listed in Table 1 .
Patient conditioning regimen
Preparative regimens varied according to the degree of HLA matching. For patients with an HLA matched sibling donor, we use conditioning regimen A, which included cytarabine (2 g/m 2 once daily intravenously (i.v.) for 1 day), cyclophosphamide 1.8/m 2 Â 2 days, busulfan 12 mg/kg administered orally as 12 doses over 3 days, Simustine (MeCCNU) 250 mg/kg. For patients with HLA mismatched donors or unrelated donors/cord bloods, patients were conditioned with regimen B, which contained Ara-C 4/m 2 Â 2 days, cyclophosphamide 1.8/m 2 Â 2 days, busulfan 12 mg/kg administered orally in 12 doses over 3 days, Simustine (MeCCNU) 250 mg/kg, and ATG (rabbit ATG 2.5 mg/kg once daily i.v. for 4 days, SangStat S.A.S., France or pig ATG 20 mg/kg once daily i.v. for 4 days, Wuhan, China). 15 A total of 36 patients received bone marrow plus peripheral blood-derived stem cells. The total amount of hematopoietic mononucleated cells (MNC) was 4-6 Â 10 
aGVHD prophylaxis
All patients except two who underwent cord blood transplantation received CsA, mycophenolate mofetil (MMF) and MTX to prevent GVHD. The dose of MTX was 15 mg/m 2 i.v. on day þ 1, followed by 10 mg/m 2 i.v. on days þ 3, þ 6, and þ 11 after transplantation. The dose of MMF was 0.5 q12h orally from day 9 before transplantation to day þ 30. The dosage of CsA was 2.5 mg/kg per day intravenously from day 9 before transplantation until bowel function was normal, at which time the patient was switched to oral CsA at half the dose. Whole blood CsA concentrations were monitored weekly using a fluorescence polarization immunoassay. The level of CsA was adjusted to between 150 and 250 ng/ml. From days þ 40 to þ 50, the dose was reduced gradually and was stopped around day þ 180, if there was no evidence of cGVHD. If cGVHD developed, CsA was continued. For patients undergoing cord blood transplantation, MP (0.5 mg/kg once daily i.v.) was added instead of MTX and MMF to the abovementioned regimen from day 1 post transplantation, as prophylaxis for aGVHD.
Supportive care
All patients were hospitalized in rooms with high-efficiency air filters and received standard antibiotic prophylactic therapy with oral trimethoprim-sulfamethoxazole, fluconazole, and acyclovir. Immunoglobulins were given intravenously at a dose of 400 mg/kg on day þ 1, þ 11, þ 21, and þ 31 after transplantation. Patients received transfusions if hemoglobin or platelet levels were below 70 g/l or 20 Â 10 9 cells/l, respectively. All blood products were irradiated.
Diagnosis and grading of GVHD
Diagnoses and gradings of aGVHD were made according to accepted criteria. 16 cGVHD was classified into several categories including: limited and extensive cGVHD, in accordance with the extent of the disease; progressive cGVHD, whether it followed as a direct extension from aGVHD; quiescent cGVHD, if prior aGVHD had completely resolved; and de novo cGVHD, if there was no prior aGVHD at all.
2,6
Immunosuppressive agents before treatment with MTX Before treatment with MTX, of 19 patients with aGVHD, 14 had not responded to MP 0.5-1 mg/kg once or in divided doses daily i.v. for at least 3 days. The remainder received no additional immunosuppressive agents.
Of 21 patients with cGVHD, 20 developed cGVHD while still taking immunosuppressive agents including low-dose prednisone (5-20 mg p.o. once daily) plus CsA (50-150 mg p.o. in divided doses daily). Nine of the 20 patients were receiving MMF at a dose of 0.5-1 g p.o. in divided doses daily, and 1 MMF together with thalidomide 300 mg p.o. once daily. Another patient developed cGVHD on no immunosuppressive agents. Three of 20 patients tried prednisone at a dose of 0.5-1 mg/kg p.o. once daily for 7-10 days, but with (NR).
Two patients with post-DLI GVHD received low-dose prednisone (12.5 and 17.5 mg p.o. once daily, respectively) plus CsA (2.5 and 3 mg/kg p.o. in divided doses daily, respectively).
Prior to the initiation of treatment with MTX, three patients suffered from hemorrhagic cystitis and one patient with aGVHD suffered a penis infection, one patient with cGVHD suffered from interstitial pneumonia. The others had no serious complications.
Treatment regimen and monitoring
MTX was given intravenously at a dose of 5 or 10 mg, repeated at day 3 or 4 after the first dose, until the patients showed a complete or partial response (PR), treatment failure or intolerable side effects. Drug dosage was adjusted according to the hemogram. MTX was administered at a dose of 5 mg if WBC o2 Â 10 9 /l or platelet o50 Â 10 9 /l. Otherwise, it was administered at a dose of 10 mg.
Patients remained on the original immunosuppressive regimen when they started MTX therapy. Later, prednisone, CsA and other immunosuppressive agents were gradually tapered off if their GVHD was under control with the addition of MTX. The patient receiving no immunosuppressive therapy prior to cGVHD received MTX alone.
Prior to initiation of the treatment, patients underwent a thorough evaluation to ascertain the severity and extent of GVHD, including physical examination, laboratory evaluation and consultation. Patients with aGVHD and post-DLI GVHD were evaluated daily, and those with cGVHD were evaluated three times per week after therapy.
Response evaluation
Complete response (CR) was defined as resolution of all clinical manifestations of GVHD. PR was defined as greater than 50% improvement in GVHD symptoms or objective parameters in at least one affected organ, but not CR. Patients were considered to have NR if GVHD progressed or failed to improve after two administrations of MTX, or if they had received an accumulated dose of more than 20 mg in 7 days in patients with aGVHD. In patients with cGVHD, NR was concluded if they received a third dose of MTX, or if they had received an accumulated dose of more than 30 mg in 1 month.
Statistical methods
Data were retrospectively collected on case report forms by medical record review. Response rates for different organs were assessed by univariate analyses using chi-squared statistics.
Results
Type of GVHD
Among the 19 patients with aGVHD, four were evaluated as grade I and 15 as grade II. Among 21 patients with cGVHD, 13 had skin involvement manifesting as lichenoid papules, 14 with liver involvement had elevation of enzymes (two accompanied by an elevated bilirubin), and 12 patients presented with thrombocytopenia.
Responses
Responses of the three types of GVHD are shown in Table 2 . In patients with aGVHD, 18 (94.7%) of 19 patients achieved a response; only one patient who had gut and liver involvement did not improve. In patients with cGVHD, 16 (76.2%) of 21 patients achieved a response: in those with limited cGVHD, five (55.6%) of nine got a response; in patients with extensive cGVHD, 11 (91.7%) of 12 were responsive; in patients with quiescent onset, 10 (90.9%) of 11 achieved a response; in patients with a de novo presentation, six (60.0%) of 10 achieved a response. Both the patients (100%) with post-DLI GVHD experienced complete resolution of GVHD.
Involved organs
Responses of involved organs are shown in Table 3 . The response rate was 100% in skin, 75% in gut, 55.6% in liver, 75% in mouth and 100% in eye among all enrolled patients. Response rates and CR rates for skin involvement were higher, or significantly higher, than those for liver involvement regardless of the type of GVHD: 93.3 vs 33.3%, P ¼ 0.059 and 100 vs 33.3%, P ¼ 0.020, respectively, in Group aGVHD, and .92.3 vs 42.9%, P ¼ 0.009 and 100 vs 57.1%, P ¼ 0.010, respectively in Group cGVHD. No statistical difference in response rates between any other organs was observed.
The number of involved organs
Among patients with aGVHD, 13 (100%) of 13 with single organ (12 patients with skin and one patient with gut) involvement resolved completely, five (83.3%) of 6 patients with two organs involvement achieved a response (CR in three patients, PR in two patients and NR in one patient). The CR rate of patients with single organ involvement was significantly higher than that of patients with two organ involvement (100 vs 50%, P ¼ 0.021). There was no statistical difference in response rates between the two groups. Among patients with cGVHD, seven (58.3%) of 12 with single organ (skin or liver) involvement had improvement (CR in five patients, PR in two and NR in five with liver involvement), nine (100%) of patients with at least two organ involvement responded (CR in three patients and PR in six patients). Responses were not related to the number of involved organs. Both patients with post-DLI GVHD with single or multiple organ involvement showed a CR.
Four patients, whose previous aGVHD had been completely controlled by MTX, experienced cGHVD subsequently. After rechallenging with MTX, three achieved a CR, and the remaining one achieved a PR.
MTX was also observed to be effective in some cases of relapse. Two patients with aGVHD grade I, two with extensive cGVHD and one with post-DLI GVHD obtained a CR after MTX, but the GVHD flared up again after a median of 15 days (range, 14-32 days) from the end of the therapy. They were given MTX again and achieved a further response. The four patients with either acute or chronic GVHD experienced a complete resolution, while the last one with post-DLI GVHD had a partial remission. He improved further with additional high-dose prednisone, but the skin rash recurred after 60 days while the prednisone was being gradually reduced. He attained a third PR with MTX.
Drug dosage
The usage of MTX in responding patients is depicted in Table 4 . Most attained a rapid resolution after the first administration of MTX.
Among the 18 patients with aGVHD, the median time to achieving a CR or PR was 10.5 days (range, 1-21 days) and the median overall dose of MTX was 20 mg (range, 5-50 mg). In all, 13 patients tapered off prednisone after achieving a response. Among the 16 patients with cGVHD, the median time to achieving a CR or PR was 21 days (range, 14-62 days) and the median overall dose of MTX was 30 mg (range, 10-60 mg). In all, 12 patients tapered off prednisone and/or CsA, six tapered off MMF after achieving a response. Eight of 15 patients with aGVHD and 11 of 16 with cGVHD received intensive therapy. Two patients with post-DLI GVHD had a CR at day 30 after MTX administration and received the drug at overall doses of 35 and 45 mg, respectively. Both of them tapered off prednisone and one of them tapered off CsA.
Toxicity
Hematologic toxicity was the most common side effect during treatment. Overall, three (15.8%) of the 19 patients with aGVHD, three (14.3%) of the 21 patients with cGVHD and one (50%) of the two patients with post-DLI GVHD developed severe leukopenia (white blood cell o2 Â 10 9 /l), three (15.8%) of the 19 patients with aGVHD developed severe thrombocytopenia (platelets o20 Â 10 9 /l). Patients with severe thrombocytopenia were given platelet transfusions, and the others received no intervention. Cytopenia was reversible in the setting of maintaining MTX therapy or after the regimen. No patient discontinued the medication or was withdrawn from the study because of hematologic side effects. Therapy-related infection, hemorrhage or nonhematologic toxicities were not observed.
During treatment, three patients with aGVHD hemorrhagic cystitis did not progress. One patient suffered from a penile infection, which improved on administration of antibiotics. One patient with cGVHD with interstitial pneumonia remained stable.
Follow-up
With a median follow-up of 24 months (range, 8-38 months), three patients (two in Group aGVHD and one in Group cGVHD) died from multiple organ failure, interstitial pneumonia and leukemia relapse, respectively, the remainder remain alive and disease-free.
Discussion
aGVHD and cGVHD are considered the most important complications after allo-HSCT and significantly compromise overall survival rates and quality of life of patients. Some patients fail conventional immunosuppressive therapy and succumb to depression of their immune system from GVHD and secondary infection. We became interested in MTX as a first line agent for the treatment of acute, chronic or post-DLI GVHD because of its immunosuppressive properties in the prevention of aGVHD post transplant.
Many drugs used in the past are returning to the forefront of investigation. To our knowledge, there are no published data confirming the safety and efficacy of MTX in the treatment of GVHD. Our results showed that lowdose MTX was safe and effective for the therapy of acute, chronic or post-DLI GVHD. It proved that MTX is of sufficient use to merit its introduction into more extensive clinical trials.
The overall response rate was 94.7% in patients with aGVHD, 76.2% in those with cGVHD and 100% in patients with post-DLI GVHD. The results were particularly good for patients with skin involvement, which is usually the first manifestation of GVHD. Therefore, early initiation of drug therapy may be more effective. Gaziev et al used three or more drugs in combination for the treatment of cGVHD. They found that patients receiving the three drug regimen as first line therapy had higher CR rates and fewer complications than did those receiving this combination as salvage treatment 12 while we found that MTX therapy effected a rapid response. GVHD-related symptoms in most patients improved within a few days and were controlled within 2-3 weeks after initiation of MTX. MTX was also effective on recurrent GVHD, which had previously responded to MTX. With the clinical improvement in GVHD after MTX, most of the patients were able to either discontinue or reduce other immunosuppressive agents such as CsA, MP or MMF, which may be beneficial in the recovery of immune function. This may explain why the use of MTX did not cause an exacerbation of infection. It should be emphasized that most patients given MTX did receive other immunosuppressive agents such as CsA and MP (or prednisone), so a synergistic effect of MTX with other drugs may exist. However, our results confirmed that MTX was effective against GVHD, which had failed to Table 4 Usage of MTX in patients who had a response respond to MP or CsA/prednisone, at least in some patients. It must be emphasized that most of our patients were not in advanced stages of disease, nor were there poor prognostic factors involved, which may contribute to our encouraging outcome. Effects of MTX on severe aGVHD or cGVHD with poor prognostic factors such as progressive onset, extensive disease, thrombocytopenia or elevation of bilirubin 2, 5, 6, 17 should be evaluated in large-scale clinical trials.
A few patients developed severe cytopenias during therapy, which indicated that the hematologic regenerative ability of the bone marrow was still poor even several months after transplantation. No other well-described side effects such as mucositis or liver dysfunction were observed. Low-dose, short-term use of MTX contributed to its safety. It is therefore suggested that the timing and schedule of the regimen should be carefully considered and a hemogram should be monitored regularly after initiation of MTX.
Previous reports have confirmed that MTX is effective in decreasing the relapse rate of leukemia if it is used alone compared to combined MTX/CsA for the prophylaxis of aGVHD in allo-HSCT patients. Meanwhile, MTX is likely to increase the incidence of interstitial pneumonia when it is administered over a long period of time. 11 In this study, all patients received low-dose MTX short-term. The impact on leukemia relapse and interstitial pneumonia are to be further evaluated.
In summary, our results demonstrate that low-dose MTX used short-term is tolerable and may be effective for patients with mild/moderate aGVHD, cGVHD and post-DLI GVHD after allo-HSCT. A prospective randomized trial is required to confirm the potential efficacy.
